Logo image of HSCS

HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

NASDAQ:HSCS - Nasdaq - US42254E3027 - Common Stock - Currency: USD

4.16  -1.57 (-27.4%)

After market: 4.27 +0.11 (+2.64%)

Fundamental Rating

3

Taking everything into account, HSCS scores 3 out of 10 in our fundamental rating. HSCS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of HSCS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, HSCS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

HSCS had negative earnings in the past year.
HSCS had a negative operating cash flow in the past year.
HSCS had negative earnings in each of the past 5 years.
HSCS had a negative operating cash flow in each of the past 5 years.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

HSCS's Return On Assets of -115.80% is on the low side compared to the rest of the industry. HSCS is outperformed by 84.49% of its industry peers.
With a Return On Equity value of -369.69%, HSCS is not doing good in the industry: 86.63% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -115.8%
ROE -369.69%
ROIC N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

HSCS has a better Gross Margin (67.20%) than 73.80% of its industry peers.
HSCS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for HSCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.91%
GM growth 5YN/A
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

5

2. Health

2.1 Basic Checks

HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
HSCS has less shares outstanding than it did 1 year ago.
HSCS has a better debt/assets ratio than last year.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -21.12, we must say that HSCS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HSCS (-21.12) is worse than 90.91% of its industry peers.
HSCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.12
ROIC/WACCN/A
WACC8.34%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M -6M

2.3 Liquidity

A Current Ratio of 1.02 indicates that HSCS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.02, HSCS is not doing good in the industry: 89.84% of the companies in the same industry are doing better.
A Quick Ratio of 0.83 indicates that HSCS may have some problems paying its short term obligations.
HSCS has a worse Quick ratio (0.83) than 85.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.83
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

5

3. Growth

3.1 Past

HSCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.40%, which is quite impressive.
The Revenue has grown by 257.69% in the past year. This is a very strong growth!
HSCS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.10% yearly.
EPS 1Y (TTM)50.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.33%
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, HSCS will show a very strong growth in Earnings Per Share. The EPS will grow by 24.81% on average per year.
The Revenue is expected to grow by 358.08% on average over the next years. This is a very strong growth
EPS Next Y80.6%
EPS Next 2Y36.08%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y289.58%
Revenue Next 3Y358.08%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2026 2027 1M 2M 3M 4M 5M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -20 -40 -60

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSCS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

HSCS's earnings are expected to grow with 24.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.08%
EPS Next 3Y24.81%

0

5. Dividend

5.1 Amount

No dividends for HSCS!.
Industry RankSector Rank
Dividend Yield N/A

HEARTSCIENCES INC

NASDAQ:HSCS (7/11/2025, 8:21:10 PM)

After market: 4.27 +0.11 (+2.64%)

4.16

-1.57 (-27.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)N/A N/A
Inst Owners3.22%
Inst Owner Change0%
Ins Owners4.5%
Ins Owner Change0%
Market Cap4.49M
Analysts82.5
Price Target13.26 (218.75%)
Short Float %8.07%
Short Ratio1.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.05%
Min EPS beat(2)-6.31%
Max EPS beat(2)8.42%
EPS beat(4)1
Avg EPS beat(4)-107.45%
Min EPS beat(4)-426.89%
Max EPS beat(4)8.42%
EPS beat(8)3
Avg EPS beat(8)-53.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 241.55
P/FCF N/A
P/OCF N/A
P/B 2.51
P/tB 25.21
EV/EBITDA N/A
EPS(TTM)-26.29
EYN/A
EPS(NY)-7.54
Fwd EYN/A
FCF(TTM)-6.94
FCFYN/A
OCF(TTM)-6.81
OCFYN/A
SpS0.02
BVpS1.65
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.8%
ROE -369.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.2%
FCFM N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.91%
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 335.88%
Cap/Sales 709.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 0.83
Altman-Z -21.12
F-Score3
WACC8.34%
ROIC/WACCN/A
Cap/Depr(3y)174.76%
Cap/Depr(5y)108.85%
Cap/Sales(3y)346.26%
Cap/Sales(5y)211.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.33%
EPS Next Y80.6%
EPS Next 2Y36.08%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y289.58%
Revenue Next 3Y358.08%
Revenue Next 5YN/A
EBIT growth 1Y-3.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.72%
EBIT Next 3Y-6.59%
EBIT Next 5YN/A
FCF growth 1Y-46.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.17%
OCF growth 3YN/A
OCF growth 5YN/A